- Home
- SOHU vs IMAB Comparison
SOHU vs IMAB Comparison
Compare SOHU & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHU
- IMAB
- Stock Information
- Founded
- SOHU 1996
- IMAB 2014
- Country
- SOHU China
- IMAB United States
- Employees
- SOHU N/A
- IMAB N/A
- Industry
- SOHU EDP Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SOHU Technology
- IMAB Health Care
- Exchange
- SOHU Nasdaq
- IMAB Nasdaq
- Market Cap
- SOHU 468.1M
- IMAB 394.2M
- IPO Year
- SOHU 2000
- IMAB 2020
- Fundamental
- Price
- SOHU $15.01
- IMAB $5.21
- Analyst Decision
- SOHU Strong Buy
- IMAB Strong Buy
- Analyst Count
- SOHU 1
- IMAB 6
- Target Price
- SOHU $20.00
- IMAB $7.17
- AVG Volume (30 Days)
- SOHU 57.7K
- IMAB 1.6M
- Earning Date
- SOHU 11-11-2025
- IMAB 11-02-2025
- Dividend Yield
- SOHU N/A
- IMAB N/A
- EPS Growth
- SOHU N/A
- IMAB N/A
- EPS
- SOHU 4.10
- IMAB N/A
- Revenue
- SOHU $548,588,000.00
- IMAB N/A
- Revenue This Year
- SOHU N/A
- IMAB N/A
- Revenue Next Year
- SOHU $2.29
- IMAB N/A
- P/E Ratio
- SOHU $3.65
- IMAB N/A
- Revenue Growth
- SOHU N/A
- IMAB N/A
- 52 Week Low
- SOHU $7.79
- IMAB $0.60
- 52 Week High
- SOHU $16.98
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- SOHU 43.32
- IMAB 66.44
- Support Level
- SOHU $14.83
- IMAB $3.98
- Resistance Level
- SOHU $16.32
- IMAB $4.51
- Average True Range (ATR)
- SOHU 0.40
- IMAB 0.31
- MACD
- SOHU -0.11
- IMAB 0.11
- Stochastic Oscillator
- SOHU 11.42
- IMAB 100.00
About SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).